Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells

Cell Biochemistry and Function

Volumn 32, Issue 8, 2014, Pages 683-691

  Meshkani, Reza ^a   Sadeghi, Asie ^a   Taheripak, Gholamreza ^a   Zarghooni, Maryam ^b   Gerayesh Nejad, Siavash ^a   Bakhtiyari, Salar ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TORONTO   (Canada)

^c ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; C2C12; Palmitate; PTP1B; Rosiglitazone; Skeletal muscle cells

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CASPASE 3; PALMITIC ACID; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTIDIABETIC AGENT; ENZYME INHIBITOR; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PTPN1 PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; GENE EXPRESSION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; MOUSE; MYOTUBE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; AGONISTS; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MYOBLAST;

ANILIDES; ANIMALS; APOPTOSIS; CELL LINE; CELL SURVIVAL; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; MYOBLASTS, SKELETAL; PALMITATES; PPAR GAMMA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; THIAZOLIDINEDIONES;

EID: 84919868569     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3072     Document Type: Article

References (59)

1. Mlinar B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007; 375: 20-35. DOI: S0009-8981(06)00447-5 [pii] 10.1016/j.cca.2006.07.005
2. Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol 2010: 527850. doi:10.1155/2010/527850.
3. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010 2010: 476279. doi:10.1155/2010/476279.
4. Martins AR, Nachbar RT, Gorjao R, et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis 2012; 11: 30. DOI: 1476-511X-11-30 [pii] 10.1186/1476-511X-11-30
5. MohammadTaghvaei N, Taheripak G, Taghikhani M, Meshkani R. Palmitate-induced PTP1B expression is mediated by ceramide-JNK and nuclear factor kappaB (NF-kappaB) activation. Cell Signal 2012; 24: 1964-1970. DOI: S0898-6568(12)00134-9 [pii] 10.1016/j.cellsig.2012.04.019
6. MohammadTaghvaei N, Meshkani R, Taghikhani M, Larijani B, Adeli K. Palmitate enhances protein tyrosine phosphatase 1B (PTP1B) gene expression at transcriptional level in C2C12 skeletal muscle cells. Inflammation 2011; 34: 43-48. doi:10.1007/s10753-010-9206-3.
7. Parvaneh L, Meshkani R, Bakhtiyari S, et al. Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells. Biochem Biophys Res Commun 2010; 396: 467-471. DOI: S0006-291X(10)00798-9 [pii] 10.1016/j.bbrc.2010.04.118
8. Gorgani-Firuzjaee S, Bakhtiyari S, Golestani A, Meshkani R. Leukocyte antigen-related inhibition attenuates palmitate-induced insulin resistance in muscle cells. J Endocrinol 2012; 215: 71-77. DOI: JOE-12-0160 [pii] 10.1530/JOE-12-0160
9. Gorgani-Firuzjaee S, Ahmadi S, Meshkani R. Palmitate induces SHIP2 expression via the ceramide-mediated activation of NF-kappaB, and JNK in skeletal muscle cells. Biochem Biophys Res Commun 2014. DOI: S0006-291X(14)01058-4 [pii] 10.1016/j.bbrc.2014.06.006
10. Tanner CJ, Barakat HA, Dohm GL, et al. Muscle fiber type is associated with obesity and weight loss. Am J Physiol Endocrinol Metab 2002; 282: E1191-1196. doi:10.1152/ajpendo.00416.2001.
11. Warmington SA, Tolan R, McBennett S. Functional and histological characteristics of skeletal muscle and the effects of leptin in the genetically obese (ob/ob) mouse. Int J Obes Relat Metab Disord 2000; 24: 1040-1050.
12. Tamilarasan KP, Temmel H, Das SK, et al. Skeletal muscle damage and impaired regeneration due to LPL-mediated lipotoxicity. Cell Death Dis 2012; 3: e354. DOI: cddis201291 [pii] 10.1038/cddis.2012.91
13. Yang M, Wei D, Mo C, et al. Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis 2013; 12: 104. DOI: 1476-511X-12-104 [pii] 10.1186/1476-511X-12-104
14. Yuzefovych L, Wilson G, Rachek L. Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal muscle cells: role of oxidative stress. Am J Physiol Endocrinol Metab 2010; 299: E1096-1105. DOI: ajpendo.00238.2010 [pii] 10.1152/ajpendo.00238.2010
15. Turpin SM, Lancaster GI, Darby I, Febbraio MA, Watt MJ. Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E1341-1350. DOI: 00095.2006 [pii] 10.1152/ajpendo.00095.2006
16. Jucker BM, Schaeffer TR, Haimbach RE, et al. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 2002; 51: 2066-2073.
17. Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001; 50: 1294-1300. DOI: S0026-0495(01)63948-9 [pii] 10.1053/meta.2001.27202
18. Nemanich S, Rani S, Shoghi K. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-gamma therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats. Obesity (Silver Spring) 2013; 21: 2522-2529. doi:10.1002/oby.20378.
19. Hevener AL, Reichart D, Janez A, Olefsky J. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. Diabetes 2001; 50: 2316-2322.
20. Miao R, Xu T, Liu L, et al. Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med 2011; 2: 413-417. doi:10.3892/etm.2011.227.
21. Zhang YQ, Tang XQ, Sun L, et al. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 2007; 13: 1534-1540.
22. Kim YJ, Park KJ, Song JK, et al. The PPARgamma agonist protects cardiomyocytes from oxidative stress and apoptosis via thioredoxin overexpression. Biosci Biotechnol Biochem 2012; 76: 2181-2187. DOI: DN/JST.JSTAGE/bbb/120423 [pii]
23. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008; 10: 617-625. DOI: DOM745 [pii] 10.1111/j.1463-1326.2007.00745.x
24. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004; 89: 5059-5066. DOI: 89/10/5059 [pii] 10.1210/jc.2004-0446
25. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90: 6678-6686. DOI: jc.2005-0079 [pii] 10.1210/jc.2005-0079
26. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 278: 10297-10303. doi:10.1074/jbc.M212307200M212307200 [pii].
27. Peterson JM, Wang Y, Bryner RW, Williamson DL, Alway SE. Bax signaling regulates palmitate-mediated apoptosis in C(2)C(12) myotubes. Am J Physiol Endocrinol Metab 2008; 295: E1307-1314. DOI: 00738.2007 [pii] 10.1152/ajpendo.00738.2007
28. Yuzefovych LV, Solodushko VA, Wilson GL, Rachek LI. Protection from palmitate-induced mitochondrial DNA damage prevents from mitochondrial oxidative stress, mitochondrial dysfunction, apoptosis, and impaired insulin signaling in rat L6 skeletal muscle cells. Endocrinology 2012; 153: 92-100. DOI: en.2011-1442 [pii] 10.1210/en.2011-1442
29. Taheripak G, Bakhtiyari S, Rajabibazl M, Pasalar P, Meshkani R. Protein tyrosine phosphatase 1B inhibition ameliorates palmitate-induced mitochondrial dysfunction and apoptosis in skeletal muscle cells. Free Radic Biol Med 2013; 65: 1435-1446. DOI: S0891-5849(13)00622-9 [pii] 10.1016/j.freeradbiomed.2013.09.019
30. Zabolotny JM, Haj FG, Kim YB, et al. Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 2004; 279: 24844-24851. doi: 10.1074/jbc.M310688200M310688200 [pii].
31. Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma). Ann Endocrinol (Paris) 2002; 63: 511-523. DOI: MDOI-AE-12-2002-63-6-0003-4266-101019-ART1 [pii]
32. Meshkani R, Adeli K. Mechanisms linking the metabolic syndrome and cardiovascular disease: Role of hepatic insulin resistance. J Tehran Univ Heart Center 2009; 4: 77-84.
33. Natalicchio A, Labarbuta R, Tortosa F, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia 2013; 56: 2456-2466. doi:10.1007/s00125-013-3028-4.
34. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52: 726-733.
35. Adams JM, 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53: 25-31.
36. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003; 419: 101-109. DOI: S0003986103004648 [pii]
37. Bryner RW, Woodworth-Hobbs ME, Williamson DL, Alway SE. Docosahexaenoic Acid protects muscle cells from palmitate-induced atrophy. ISRN Obes 2012; 2012: 647348. doi:10.5402/2012/647348.
38. Rachek LI, Musiyenko SI, LeDoux SP, Wilson GL. Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. Endocrinology 2007; 148: 293-299. DOI: en.2006-0998 [pii] 10.1210/en.2006-0998
39. Henique C, Mansouri A, Fumey G, et al. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J Biol Chem 2010; 285: 36818-36827. DOI: M110.170431 [pii] 10.1074/jbc.M110.170431
40. Wu J, Wu JJ, Yang LJ, Wei LX, Zou DJ. Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5'-AMP-activated protein kinase modulation. Endocrine 2013; 44: 87-98. doi:10.1007/s12020-012-9826-5.
41. Wang AP, Li X, Zheng Y, et al. Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPARgamma-dependent mechanisms. Acta Diabetol 2013; 50: 163-173. doi:10.1007/s00592-010-0239-8.
42. Abaraviciene SM, Lundquist I, Salehi A. Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities. Cell Mol Life Sci 2008; 65: 2256-2265. doi:10.1007/s00018-008-8100-8.
43. Kang SB, Kim HM, Kim HJ, et al. Rosiglitazone attenuates casein-induced hepatic endoplasmic reticulum stress in Sprague-Dawley rats: a novel model of endoplasmic reticulum stress. Endocr J 2013; 60: 1231-1240. DOI: DN/JST.JSTAGE/endocrj/EJ13-0167 [pii]
44. Schuster M, Zouboulis CC, Ochsendorf F, et al. Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne? Br J Dermatol 2011; 164: 182-186. doi:10.1111/j.1365-2133.2010.10037.x.
45. Liu JJ, Dai XJ, Xu Y, et al. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-gamma ligands via Wnt signaling pathway. Cell Biochem Biophys 2012; 62: 19-27. doi:10.1007/s12013-011-9253-x.
46. Cao LQ, Chen XL, Wang Q, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007; 28: 879-887. doi:10.1111/j.1745-7254.2007.00571.x.
47. Kim KY, Ahn JH, Cheon HG. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Mol Pharmacol 2007; 72: 674-685. DOI: mol.107.035584 [pii] 10.1124/mol.107.035584
48. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 2012; 287: 23517-23526. DOI: M111.324814 [pii] 10.1074/jbc.M111.324814
49. Gum RJ, Gaede LL, Koterski SL, et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003; 52: 21-28.
50. Gonzalez-Rodriguez A, Escribano O, Alba J, Rondinone CM, Benito M, Valverde AM. Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes. J Cell Physiol 2007; 212: 76-88. doi:10.1002/jcp.21004.
51. Song H, Zhang Z, Wang L. Small interference RNA against PTP-1B reduces hypoxia/reoxygenation induced apoptosis of rat cardiomyocytes. Apoptosis 2008; 13: 383-393. doi:10.1007/s10495-008-0181-1.
52. Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML, Chevet E. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem 2004; 279: 49689-49693. DOI: C400261200 [pii]10.1074/jbc.C400261200
53. Bettaieb A, Liu S, Xi Y, et al. Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and T cell protein tyrosine phosphatase. J Biol Chem 2011; 286: 9225-9235. DOI: M110.186148 [pii]10.1074/jbc.M110.186148
54. Traves PG, Pardo V, Pimentel-Santillana M, et al. Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge. Cell Death Dis 2014; 5: e1125. DOI: cddis201490 [pii]10.1038/cddis.2014.90
55. Egawa K, Maegawa H, Shimizu S, et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J Biol Chem 2001; 276: 10207-10211. DOI: 10.1074/jbc.M009489200M009489200 [pii]
56. Bakhtiyari S, Meshkani R, Taghikhani M, Larijani B, Adeli K. Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 2010; 45: 237-244. doi:10.1007/s11745-010-3394-3.
57. Hernandez R, Teruel T, Lorenzo M. Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes. Diabetologia 2003; 46: 1618-1628. doi:10.1007/s00125-003-1236-z.
58. Planavila A, Alegret M, Sanchez RM, Rodriguez-Calvo R, Laguna JC, Vazquez-Carrera M. Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice. Biochem Pharmacol 2005; 69: 1195-1204. DOI: S0006-2952(05)00069-9 [pii] 10.1016/j.bcp.2005.01.015
59. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003; 52: 1943-1950.